#039;M) Trend; Long Term Outlook – No change; FY23 Updated Outlook; Creating a better future for health." /> #039;M) Trend; Long Term Outlook – No change; FY23 Updated Outlook; Creating a better future for health." /> #039;M) Trend; Long Term Outlook – No change; FY23 Updated Outlook; Creating a better future for health." />

Beamtree Holdings Ltd · ASX:BMT

Beamtree — Q3 FY23 Earnings Presentation

17 slides from Beamtree's earnings presentation, Apr 27, 2023

  1. Slide 1: Q3 FY23 Trading Update

    Q3 FY23 Trading Update 27 April, 2023

  2. Slide 2: Important Notice and Disclaimer

    Important Notice and Disclaimer The material in this presentation is general background information about Beamtree Holdings Limited (ASX:BMT) and is current at the date of the presentation, 27 April 2023. This presentation may contain statements that are, or may be deemed to be, forward looking stat

  3. Slide 3: Q3 FY23 Highlights

    Q3 FY23 Highlights Copyright © Beamtree Holdings Limited – All Rights Reserved 2

  4. Slide 4: Q3 FY23 Key Strategic Highlights

    Q3 FY23 Key Strategic Highlights ▪ Abbott partnership continues to deliver to expectations with 11 new licences in FY23 YTD compared to 27 over the previous 6 years. Recurring revenue from the partnership has doubled in FY23. ▪ Awarded an implementation of RippleDown into the Coventry & Warwickshire

  5. Slide 5: Annual Recurring Revenue (ARR) Growth ($'M) Trend

    Annual Recurring Revenue* (ARR) Growth ($’M) Trend + ~20% organic PCP 21.0 • + ~20% PCP organic growth 20.1 in Annual Recurring Revenue 19.1 (ARR) largely driven by international growth. 18.2 17.3 • Almost 60% of organic ARR 16.8 growth was driven by our Diagnostics segment with the remaining growth

  6. Slide 6: Long Term Outlook – No change

    Long Term Outlook – No change Main Drivers of Growth: ~70% of the growth will come from overseas market ARR $60M ▪ Abbott (3+2 year) contract with revenue share 35% CAGR ~35-40% ▪ International direct RippleDown sales ARR $20M ~15-20% ▪ Sales of CDS (Ainsoff AI) products both in ANZ and ~15-20% Inte

  7. Slide 7: FY23 Updated Outlook

    FY23 Updated Outlook Management reaffirms long term outlook of delivering annual recurring revenue of $60m by 2026. Q3 trading supports FY23 organic recurring revenue growth forecast to be ~20%. Strategic international projects continue to underline growth going into FY24. Continued focus on cost ma

  8. Slide 8: Beamtree Strategy

    Beamtree Strategy Copyright © Beamtree Holdings Limited – All Rights Reserved 7

  9. Slide 9: Creating a better future for health

    Creating a better future for health We provide AI decision support and data insights solutions with the aim of turning data into insights and action through automation. We believe it starts with better data and ends in better care – and that ‘better has no limit’

  10. Slide 10: About Us

    me Australian company with Supporting healthcare Cutting-edge use of Al Australian IP globally and machine learning kan | </> AS LQ. == 40% nti! Diagnostic Technology _ Clinical Decision Support | Coding Assistance & Analytics & Knowledge leaders in acute care Data Quality Networks

  11. Slide 11: Beamtree's History

    Beamtree’s History Pacific Knowledge Systems ¢ Est. 1999 - Listed 2019 RippleDown —-RippleDown’ Auditor Expert, Ainsoff Est. 2018 - Acq. 2021 ISAT AB

  12. Slide 12: Supporting Healthcare Providers Globally

    Supporting Healthcare Providers Globally

  13. Slide 13: Learning Health Systems

    Learning Health Systems Driving continuous improvement by better access to healthcare information — towards safety, quality a

  14. Slide 14: The Problems We Help Solve

    The Problems We Help Solve Ce Tackle unwarranted Offer revenue Promote transparency variation assurance Address equity Bridge knowledge gaps Increase efficiency, of access and resource reducing mistakes allocation Drive automation (\\ A Improve quality of data

  15. Slide 15: Our product segments

    Our product segments Coding Assistance and Data Quality Diagnostic Technology Digitising and automating workflows with data, Enabling the effective delivery of diagnostic classification, coding & technical expertise to services as they underpin the future of health improve information standardisatio

  16. Slide 16: Key Areas, Key Products and What They Do

    Key Areas, Key Products and What They Do Product/ Solutions Application Problem Solved ROI Pricing/Scale Leverages scarce clinical Removes duplication Recurring Clinical rules to automate resources through for experts in License + volume expert decision making in Diagnostics automating and providing

  17. Slide 17: Thank you

    Thank you Copyright © Beamtree Holdings Limited – All Rights Reserved 16

Beamtree Holdings — Q3 FY23 Earnings Presentation on 6ix